Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy

Panminerva Medica

Volumn 46, Issue 4, 2004, Pages 239-251

  Weller, R O ^a,b   Cohen, N R ^a   Nicoll, J A R ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Alzheimer disease; Cerebrovascular dementia diseases, physiopathology; Cerebrovascular diseases, diagnosis; Dementia

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; BIOLOGICAL MODEL; BRAIN; CEREBROVASCULAR DISEASE; EXTRACELLULAR FLUID; HUMAN; METABOLISM; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CEREBROVASCULAR DISORDERS; DEMENTIA, VASCULAR; EXTRACELLULAR FLUID; HUMANS; MODELS, NEUROLOGICAL; NEUROFIBRILLARY TANGLES; RISK FACTORS;

EID: 20044366064     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262:2551-6.
2. Fujishima M, Kiyohara Y. Incidence and risk factors of dementia in a defined elderly Japanese populaton. Ann N Y Acad Sci 2002;977: 1-8.
3. Suh GH, Shah A. A review of the epidemiological transition in dementia. Cross national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatr Scand 2001;104:4-11.
4. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999;354:919-20.
5. Wu CC, Mungas D, Eberling J.L, Reed B.R, Jagust WJ. Imaging interactions between Alzheimer's disease and cerebrovascular disease. Ann NY Acad Sci 2002;977:403-10.
6. Korczyn AD. Mixed dementia. The most common cause of dementia. Ann N Y Acad Sci 2002;977:129-34.
7. Weatherall D, Ledingham JGG, Warrell DA. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1996.
8. Sagar HJ, Sullivan EV. Patterns of cognitive impairment in dementia. In: Kennard C, editor. Recent Advances in clinical neurology. Edinburgh: Churchill Livingstone; 1988.
9. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 2004;75:61-71.
10. Bayer TA, Jakala P, Hartmann T, Havas L, McLean C, Culvenor JG et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci Lett 1999;266:213-6.
11. Bowen JD. Dementia. Med Clin North Am 2002;86:455-76.
12. Goldfarb LG, Brown P. The transmissible spongiform encephalopathies. Annu Rev Med 1995;46:57-65.
13. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000;47:575-82.
14. Nagasawa S, Handa H, Okumura A, Naruo Y, Moritake K, Hayashi K. Mechanical properties of human cerebral arteries. Part I. Effects of age and vascular smooth muscle activation. Surg Neurol 1979;12: 297-304.
15. Xu Q. Mouse models of arteriosclerosis. Am J Pathol 2004;165: 1-10.
16. Thai DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer's disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 2003;62:1287-301.
17. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
18. Morris JH, Kalimo H, Viitanen M. Vascular dementias. In: Esiri MM, Lee VMY, Trojanowski JQ, editors. The neuropathology of dementia. 2nd ed. Cambridge: Cambridge University Press; 2004 p. 289-329.
19. Kalimo H, Ruchoux M-M, Vitanen M, Kalaria RN. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 2002;12:371-84.
20. Ruchoux MM, Guerouaou D, Vandenhaute B, Pruvo JP, Vermersch P, Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol 1995;89:500-12.
21. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59.
22. Morris JH, Nagy Z. Alzheimer's disease. In: Esiri MM, Lee VMY, Trojanowski JQ, editors. The neuropathology of dementia. 2nd ed. Cambridge: Cambridge University Press; 2004. p. 161-206.
23. Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol 2004;204:438-49.
24. Layfield R, Alban A, Mayer RJ, Lowe J. The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 2001;27:171-9.
25. Layfield R, Cavey JR, Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003;2:343-56.
26. Vonsattel JPG, Lianski M. Huntington's disease. In: Esiri MM, Lee VMY, Trojanowski JQ, editors. The neuropathology of dementia. 2nd ed. Cambridge: Cambridge University Press; 2004. p. 376-401.
27. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004;22:453-65.
28. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
29. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-62.
30. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46: 860-6.
31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al. The consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization for the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
32. Mueggler T, Rausch M, Meyer-Luehmann M, Staufenbiel M, Jucker M, Rudin M. Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis. Eur J Neurosci 2004;20:811-7.
33. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21: 383-421.
34. Scholz W. Studien zur Pathologie der Hirngefaesse II. Die drusige Entartung der Hirnarterien und -capillaren. (Ein Form seniler Gefaesserkrankung). ZGesamte Neurol Psychiatr 1938;162: 694-715.
35. Rensink AAM, deWaal RMW, Kremer B, Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. Brain Res Rev 2003;43:207-23.
36. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885-98.
37. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33.
38. Preston SD, Steart PV, Wilkinson A, Nicoll JAR, Weller RO. Capillary and arterial amyloid angiopathy: deliniation of the perivascular route for elimination of amyloid-beta from the human brain. Neuropathol Appl Neurobiol 2003;29:106-117.
39. Thai DR, Ghebremedhin E, Rub U, Yamaguchi H, Tredici KD, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002;61:282-93.
40. Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol 2000;157:1283-98.
41. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-75.
42. Wisniewski HM, Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol (Berl) 1994;87:233-41.
43. McCarron MO, Nicoll JA, Ironside JW, Love S, Alberts MJ, Bone I. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. Stroke 1999;30: 1643-6.
44. Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996;6:179-95.
45. Nicoll JAR, Yamada M, Frackowiak J, Mazur Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging 2004;25:589-97.
46. Cserr HF, Ostrach LH. Bulk flow of interstitial fluid after intracranial injection of blue dextran 2000. Exp Neurol 1974;45:50-60.
47. Zhang ET, Richards HK, Kida S, Weller RO. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol 1992;83:233-9.
48. Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 1998;57:885-94.
49. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 2004;45: 545-52.
50. Carare-Nnadi R, Bernardes-Silva M, Subash M, Perry VH, Weller RO. Perivascular pathways for the clearance of interstitial fluid from the brain and the pathology of Alzheimer's disease. Neuropathol Appl Neurobiol 2005 (in press).
51. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO et al. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 2000;6:430-9.
52. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004;7:954-60.
53. Weller RO, Nicoll JAR. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 2003;25:611-6.
54. Shinkai Y, Yoshimura M, Ito Y, Odaka A, Suzuki N, Yanagisawa K et al. Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels. Ann Neurol 1995;38:421-8.
55. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-88.
56. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004;24:10191-200.
57. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
58. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-60.
59. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-8.
60. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-70.
61. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90: 1977-81.
62. Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000;21:245-55.
63. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000;54:1316-23.
64. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer's disease A beta amyloid peptides. Peptides 2002;23:1285-97.
65. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 2002;70:493-500.
66. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408: 979-82.
67. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52.
68. Wyss Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003;9:453-7.
69. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99.
70. Yow HY, Weller RO. A role for cerebrovascular disease in determining the pattern of beta amyloid deposition in Alzheimer's disease. Neuropathol Appl Neurobiol 2002;28:149.
71. Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JAR. Cerebrovacular diesease is a major factor in the failure of elimination of A-beta from the human brain: implications for therapy of Alzheimer's disease. Ann N Y Acad Sci 2002;977:162-8.
72. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 2004 (submitted).
73. Roher AE, Kuo Y-M, Esh C, Knebel C, Weiss N, Kalback W et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 2003;9:112-22.
74. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363: 2105-15.
75. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
76. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54.
77. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.